Search CommunityWalk:


Supernus Pharmaceuticals Inc

1550 East Gude Drive
Rockville, MD 20850, USA

Category: Drug Delivery

Used in the following map:

Maryland Biotech Industry Map

Supernus Pharmaceuticals Inc is a specialty pharmaceutical company engaged in focused on developing and commercializing products for the treatment of central nervous system (CNS) disorders. Its vision is to be a leading specialty pharmaceutical company focused on treating CNS disorders. The company was founded in December 2005 by Jack A. Khattar.

Supernus is leveraging 6 proprietary technology platforms and additional in-licensed technologies that allows the company to discover and develop novel uses for known drug compounds and to enhance their therapeutic benefits. The company's technologies include: Microtrol®, Solutrol®, etc. Its technologies are designed to meet specific clinical efficacy needs, permit more convenient and less frequent dosing, enhance patient compliance and improve tolerability in specific applications.

Supernus' product pipeline portfolio includes: Neurology Portfolio and Psychiatry Portfolio. The company's Neurology Portfolio includes: SPN-538 - a novel, oral, extended-release, once-daily formulation of topiramate for the treatment of epilepsy; and Epliga® - a novel, oral, once-daily, extended-release formulation of oxcarbazepine for the treatment of epilepsy. Its Psychiatry Portfolio includes: SPN-810 - a novel treatment for impulsive aggression in patients with ADHD; SPN-812 - a novel nonstimulant treatment for ADHD; and SPN-809 - a novel once-daily norepinephrine reuptake inhibitor for the treatment of depression.

Supernus has collaborations with Daewoong Pharmaceutical Co Ltd, Depomed Inc, United Therapeutics Corp and Endo Pharmaceuticals Solutions Inc (formerly Indevus Pharmaceuticals Inc; Interneuron Pharmaceuticals Inc).